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Background: Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM
therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH
clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics
for rapid entry into clinical trials for GBM.
Methods: Screens using human GBM cell lines revealed 22 drugs with potent anti-GBM activity, including
serotonergic blockers, cholesterol-lowering agents (statins), antineoplastics, anti-infective, anti-inflammatories,
and hormonal modulators. We tested the 8 most potent drugs using patient-derived GBM cancer stem cell-like
lines. Notably, the statins were active in vitro; they inhibited GBM cell proliferation and induced cellular autophagy.
Moreover, the statins enhanced, by 40-70 fold, the pro-apoptotic activity of irinotecan, a topoisomerase 1 inhibitor
currently used to treat a variety of cancers including GBM. Our data suggest that the mechanism of action of statins
was prevention of multi-drug resistance protein MDR-1 glycosylation. This drug combination was synergistic in
inhibiting tumor growth in vivo. Compared to animals treated with high dose irinotecan, the drug combination
showed significantly less toxicity.
Results: Our data identifies a novel combination from among FDA-approved drugs. In addition, this combination
is safer and well tolerated compared to single agent irinotecan.
Conclusions: Our study newly identifies several FDA-approved compounds that may potentially be useful in GBM
treatment. Our findings provide the basis for the rational combination of statins and topoisomerase inhibitors in GBM.
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Novel therapeutic options are sorely needed to target
glioblastoma (GBM), a notoriously treatment-resistant
brain cancer. GBM is a leading cause of cancer-related
death in the pediatric and adult populations, with most
patients succumbing within 1-2 years [1,2]. The standard
therapies are inadequate, and their toxicities lead to severe
life-long morbidity in the small number of patients that
survive [2]. Despite this grim prognosis, GBM is an* Correspondence: skesari@ucsd.edu
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stated.orphan disease that is in general not a priority for new
drug development [3-5]. Moreover, the biology of GBM
is complex and much remains to be learned about the
putative key signaling pathways before they can be
therapeutically exploited [6]. In view of the unmet and
urgent clinical need, we were motivated to pursue
recent data indicating that GBM may respond to some
FDA-approved agents not previously identified as GBM
therapeutics [7,8]. The in vitro screening of a broad
range of drugs already approved for other indications is
attractive as in vivo toxicity and pharmacology are well
defined, and such compounds can enter GBM clinical
trials rapidly either as single agents or as combinations.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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single and combination agents having anti-GBM activity
that we can potentially introduce into clinical trials
quickly. To this end, using GBM cell lines and patient-
derived GBM cell cultures, we screened a 446-compound
NIH Clinical Collection (NCC) library comprising FDA-
approved drugs. To further improve the anti-GBM potency
of these drugs, we tested various drug combinations
and compared them to single drug treatment.
Our screening strategy included multiple human GBM
cell lines of different origins in order to provide
cross-validation of findings. These cell lines included
4 established serum-grown, immortalized human GBM
lines, 4 patient-derived stem cell like GBM primary cells
grown as neurospheres, and 2 primary patient-derived
GBM lines grown as adherent cultures [9-14].
We did not confine our screening to only adherent
GBM stem cell lines despite reports claiming that such
lines remain undifferentiated longer and constitute a
simpler, less variable assay [11,14]. It is not yet firmly
established that the major therapeutic target in GBM is
just the cancer stem cell tumor compartment and there
are indications that other cell types within GBM may
assume stem cell characteristics through genetic or epigen-
etic events [14-16]. In contrast to a single type or lineage
of cells, neurospheres contain a mix of GBM stem cells
and differentiated cells, which is more reflective of the
composition of human GBM tumors [17]. Further, when
dissociated neurospheres are implanted orthotopically,
they are highly tumorigenic and authentically recapitulate
the invasive natural history, composition, and histology
of GBMs growing in humans [16]. Hence we report the
identification of NCC active compounds through our
screening approach on patient-derived stem cell-like GBM
primary cells.
Our initial screening identified 22 compounds active
against GBM (>50% cell death) [18] at pharmacological
doses. These 22 compounds encompassed 11 drug classes.
In particular, we found that the statin, pitavastatin, effec-
tively induced cellular autophagy and suppressed tumor
cell MDR-1 protein, to impressively enhance the potency
of irinotecan, a topoisomerase 1 inhibitor used in cancer
treatment [19-21]. This work newly identifies FDA ap-
proved drugs and drug combinations, notably pitavastatin
and irinotecan, that may be useful for GBM treatment,
and draws attention to the potential value of in vitro
screening of approved compounds not currently used
to treat GBM.
Materials and methods
Overview of cell-based (in vitro) screening for potential
anti-GBM compounds
We acquired 446 small molecules that completed human
clinical trials from the NIH Clinical Collection (NCC).The initial broad screen was performed on U87 cells
plated at 2000 cell per well on 96-well plates incubated
overnight. All compounds were added to the plates to
attain a final concentration of 10 μM. After 72 hours of
incubation with drugs, the inhibition of cell proliferation
was quantified by the Alamar Blue viability assay. Briefly,
after incubation, Alamar Blue (#BUF012B, AbD Serotec)
was added directly to the culture medium, and the fluores-
cence measured at 560/90 to determine the number of
viable cells (Infinite M200, Tecan Group Ltd.). The IC50
values were calculated using commercially available
software (Prism®, Graphpad Software, La Jolla, CA). We
defined active compounds as those eliciting a greater
than 50% reduction of cell viability in three independent
screens. The 15 most potent and available drugs or
compounds were then re-screened with other established
glioma cell lines (LN443, A172 and U118), with the four
patient derived GBM stem cell like primary neurosphere
lines (SK72, SK262, SK429 and SK660), and with 2 GBM
stem cell like primary cells (SK72 and SK262) grown as
adherent culture. Pitavastatin was also tested in combi-
nations with the other 12 compounds. The IC50 values
were determined with and without pitavastatin (2 μM),
using the Alamar blue assay as described above.
Isolation, culture, and compound activity testing with
patient derived GBM cells
Human GBM samples
Fresh human GBM material was acquired from 4 GBM
surgical patients and cultured as previously reported [9,13].
Briefly, the dissociated tissue was washed, filtered through a
30 μm mesh and plated onto ultra-low adherence flasks at
a concentration of 500,000 to 1,500,000 viable cells/ml. The
stem cell isolation medium included human recombinant
EGF (20 ng/ml), human bFGF (10 ng/ml) and heparin
(2 μg/ml). Sphere cultures were then passaged by dissoci-
ation, washed, resuspended in neural stem cell culture
medium (#05750,Stemcell Technologies), and plated on
ultra low-adherence 96 well plates at 2000 cells per well
for all subsequent drug testing.
Alternatively, patient-derived dissociated GBM tissues
were plated onto laminin-1 coated plates (Sigma, 3-5 μg/ml).
Cell populations were dissociated using Acutase (Sigma)
and expanded for 5-10 passages, then plated on flat
bottom for drug testing.
Confirmation of stem cell marker expression
Primary neurospheres were cytospun onto glass slides.
Adherent primary cultures were grown onto Permanox™
chamber slides (#70380,EMS). Cells were incubated with
human Nestin antibody (M1259, R&D system) and then
with fluorescein-labeled secondary antibodies, then stained
with DAPI. The cells were visualized under a UV micro-
scope (Olympus BX51).
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As explained above, cells were seeded onto either regular
or ultra-low adherence 96 well plates and incubated for
18-24 hours and then treated with vehicle control or
single drugs or drug combinations. After 96 hours of
incubation, Alamar Blue was added directly to the
culture medium, and the fluorescence measured at 560/90
after 4-12 hours to determine the number of viable
cells. The IC50 was calculated.Prediction of blood brain barrier (BBB) permeation by
active compounds
Although ample evidence has demonstrated that drugs
of virtually any size or chemotype can enter brain tumor
via leaky tumor microvessels, the ability to penetrate the
intact blood brain barrier (BBB) is reasonably hypothe-
sized to be useful for treating tumor cells infiltrating
normal brain tissue along fiber tracts [22-25]. Hence we
estimated the capacity of active anti-GBM compounds to
cross the BBB. We used standard software to calculate the
Log BB value: Log BB = -0.0148 PSA + 0.152 CLogP +
0.139; PSA = polar surface area, p = octanol/water parti-
tion coefficient [26,27].Determination of cell cycle, autophagy, and apoptosis
Cell cycle analysis
GBM cells were seeded into 10 cm dishes at a density of
1 × 106, cultured overnight followed by the addition of
3 μM pitavastatin with 24 or 48 hours of incubation.
Cells were trypsinized and fixed in 70% ethanol for 30
minutes, incubated with 25 μg/ml propidium iodide (PI)
and 250 μg/ml RNAase in PBS for 1 hour at 50°C. After
PI staining, cells were analyzed via flow cytometry
(Canto, BD FACS), and the percentage of cells in G0/G1,
S and G2 phases were calculated by ModFit LT software
version 3.0.Detection of caspase activity
Caspase-3 activity was measured with the Invitrogen
Enzcheck caspase-3 assay kit #2 according to the man-
ufacture’s protocol. Briefly, 3 × 106 U118 cell were cul-
tured and pitavastatin, irinotecan or the combination
was added to the medium for 12 or 24 hours. Then 106
cells were lysed, DEVD-R110 fluorescence substrate
was added, and the fluorescence signal was measured
and compared with a standard curve (Infinite M200,
Tecan). Caspase 3/7 activity was measured by the
Apo-One caspase3/7 Kit (#G7790, Promega). 20,000
cells were seeded on to 24 well plates, pitavastatin and
vehicle were added, followed by incubation (8, 12, 24
and 48 hours) and caspase 3/7 activity was measured
using a fluorescence-based substrate.Detection of autophagy markers-GFPLC3 punctuation
Retrovirus carrying the GFPLC3 was produced by trans-
fecting the 293GP2 cells with the pVSV-G and pBABE-
puro-GFPLC3 plasmids (GFP fused with LC3 gene at
the N-terminal, Addgene #22405). Retroviral supernatants
were harvested 48 hours later. U87, U118, U251 cells were
seeded at a density of 2 × 105 in 6 well plates and infected
24 hr later with the VSV-G/GFPLC3 virus. Stable cell lines
were selected for 1 week in 1 μg/ml puromycin. GFPLC3-
expressing lines were seeded onto 24 well plates and
treated with 1 μM pitavastatin for 48 hours. Presence of
GFPLC3 punctuation, which is a marker of autophagy was
detected by UV microscopy (Olympus IX81).
Western blot analysis for autophagy, apoptosis, and
multidrug resistance protein
LC3 (autophagy), caspase-3 (apoptosis), and MDR-1
(multidrug resistance protein 1 or P-glycoprotein 1,ABCB1)
and tubulin (as loading control) were detected by western
blotting following drug treatment. Cell lysates (10-50 μg
protein) were loaded on to either 14% SDS-PAGE gel (for
LC3) or 4-12% gel (for caspase-3, and MDR-1), proteins
transferred to PVDF membrane and probed with primary
antibodies (L8918 Sigma, 9662 Cell signaling, Sc-8313
Santa Cruz, T4026 Sigma). The resultant protein bands
were visualized by a supersignal kit (#1856136,Thermo
Scientific) after incubation with HRP-labeled secondary
antibodies.
Multi-drug resistance assay
A cell-based fluorescence assay kit (Cayman Chemical
Company, MI, USA, #600370) was used to evaluate
modulation of the MDR-1 protein by drugs. Calcein
AM is a hydrophobic non-fluorescent dye that easily
permeates living cells. The hydrolysis of Calcein AM by
intracellular esterases produces calcein, a hydrophilic
strongly fluorescent compound which is retained in the
cell cytoplasm and can be measured using excitation and
emission wavelengths at 485 nm and 535 nm, respectively.
Calcein AM is a substrate of MDR-1 protein P-gp, which
causes its rapid extrusion from the plasma membrane,
preventing accumulation of the fluorescent calcein inside
the cytoplasm. Therefore measurement of fluorescent
calcein allows for detection of MDR activity in live
cells. Hoechst Dye staining of nuclei measured using of
excitation and emission wavelengths 355 nm and 465 nm
respectively to normalize cell numbers in well. GBM cells
were seeded at 5 × 104/well overnight, then pitavastatin
was added to final concentration of 1, 3 and 10 μM.
Twenty four hours after treatment, cells were incubated
for Calcein AM/Hoechst Dye solution for 15 min, then
fluorescent Calcein retention was measured 20 μM
Verapamil or cyclosporine A treatments for 20-30 min
as positive control of MDR-1 inhibition followed as the
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ratio of Calcein AM/ Hoechst signal (C/H ratio). Photo-
micrographs were taken using fluorescence microscopy.
GBM patients’ survival and free disease status relative to
MDR-1 (ABCB1) expression
The GBM patient data were obtained from The Cancer
Genome Atlas (TCGA) public data portal, and analyzed
using the cBio Cancer Genomics Portal. This system is
developed and maintained by the computational biology
center of Memorial Sloan-Kettering Cancer Center. We
investigated and regrouped GBM patients according their
MDR-1 (ABCB1) expression. Firstly, we required the
patients/case ID with the MDR-1 expression in all TCGA
GBM provisional databases. The mRNA expression z-
scores threshold were set as ±1 in our analysis. Then,
we regrouped all the patients into 3 groups according
to their MDR-1 expression as up-regulated, normal, and
down-regulated. Finally, we inputted the down-regulated
or up-regulated patients ID with normal expressed
patients to select patient/case set to analyze patient
survival and free disease status data. The Kaplan-Meier
curves were drawn based on these analyses.
Animal studies
The in vivo studies were performed on nude mice to
evaluate the drug effects on inhibition of tumor growth.
2 × 106 U87 cells were subcutaneously transplanted into
the right and left flanks. Initial tumor growth was moni-
tored every 3 days. Drug administration was initiated
when the tumors reached a size of 100-120 mm3. Mice
were regrouped into 5 groups of 6 mice each, without
significant difference in tumor volume before drug treat-
ment. The mice were treated with either PBS as control,
low dose of pitavastatin (0.5 mg/kg), low dose of irinote-
can (0.5 mg/kg), a combination of pitavastatin (0.5 mg/kg)
and irinotecan (0.5 mg/kg), or high dose of irinotecan
(5 mg/kg). All drugs were injected i.p. in 200 μl of PBS,
once per day, on a 5-days-on, 2-days-off schedule. Tumors
size and mice weight were measured 2 times per week.
All mice were sacrificed after tumor sizes reach over
1 cm in diameter in the control group. Tumor volumes
were calculated as (length*width*width/2). After sacrifice,
all tumors were disserted and weighted. The animal proto-
col was approved by UCSD Institutional Animal Care and
Use Committee (IACUC).
Statistical analysis
Activity against GBM cells was assessed by dividing the
average number of viable cells (from three replicates per
dose) by the average of three controls. At a type I error
rate of 0.05, using a one-sided t-test, we calculated 80%
power to evaluate whether a decrease in mean percent
viable cells was significantly lower than 100%, if theobserved mean percentage was 91.4%; we conservatively
assumed the standard deviation of the percent viable cells
was 15%. For significant difference by t-test (P < 0.05),
labeled * at the bar graphs.
To quantify the synergism of drug combinations, the
drug combination index (CI) was calculated as described
by Chou [28]. ED50, ED75 and ED90 were defined as the
drug dose able to inhibit cell growth 50%, 75% and 90%,
respectively, for pitavastatin alone, irinotecan alone and
mixture of two drugs (various ratios). A CI < 1 indicates
synergy between the two drugs.
Results
In vitro screening of drugs
U87 studies
The U87 in vitro cell culture platform was used to initially
screen the NCC library of 446 small molecules. We cal-
culated percent cell viability as depicted in Figure 1A,
and found that 22 drugs reduced viability to less than
50%. Figure 1B shows the specific cell viability for each of
these 22 compounds. Homoharringtonine and cerivastatin
reduced survival to 10% percent or less, while 9 compounds
reduced survival to less than 25%, 6 drugs reduced survival
to less than 35%, and the remainder was associated
with a survival of 35-50%. As single agents, all these 22
compounds are more effective in vitro than temozolomide,
a widely used drug in GBM treatment (Additional file 1).
This result is consistent with previous studies [29,30].
Nine of the 22 compounds producing <50% cell survival
were more potent than vincristine, a component of a
commonly used glioblastoma chemotherapy regimen
(procarbazine, lomustine and vincristine – PCV). Similarly,
15 of the 22 compounds were more potent that the
commonly used GBM chemotherapeutic irinotecan. As
expected, most of the compounds (13 of 22) were anti-
neoplastics and a majority of these (8) oncology drugs
are not currently used for the treatment of GBM. Three
cardiovascular compounds, cerivastatin, pitavastatin, and
nisoldipine showed activity, with the two cholesterol-
lowering agents, cerivastatin and pitavastatin having the
greatest effect. The effectiveness of statins prompted us
to test a range of commercial available statins; of which,
cerivastatin and pitavastatin have the lowest IC50 values
(unpublished data).
The two serotonergic pathway inhibitors, sertraline and
5-nonyloxytryptamine also inhibited the survival of U87
cells, which agrees with previously published findings
using an adherent GBM stem cell assay [11,12].
A172, LN443 and U118 cells
To further characterize the most potent compounds
identified in our initial screen, we re-screened, using
the established cell lines A172, LN443, and U118, the
15 compounds that showed the highest potency with
Figure 1 NIH clinical collection compounds/drugs screened in vitro with U87 human GBM cells. (A) All 446 compounds in the NCC drug
panel ordered according to percent viability after treatment, note the shoulder at the end indicating 22 agents with anti-GBM activity. (B) The 22
positive compounds retested with three replicates. (C) IC50 of the most active and available compounds screened with four widely used,
established GBM cell lines. The predicted BBB value for each compound is shown.
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potency than vincristine in all cell lines tested and 12
drugs had lower IC50 values than irinotecan. We selected
8 FDA approved drugs for further investigation using
patient-derived GBM stem cell-like cells (D-Actinomycin,
Liposome-encapsulated Doxorubicin/Doxil, Epirubicin,
Irinotecan, Pitavastatin, Sertraline, Topotecan and Vincristine).Stem cell-like GBM lines
We used GBM stem-like cells derived from surgically-
resected patient samples. Previously, using whole-exome
sequencing, we observed global conservation of the
patient’s tumor genetics in various pre-clinical models,
including neurospheres, adherent cells and xenografts
[31]. Findings from our study therefore support the
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testing of personalized targeted therapies. In the present
study, we used GBM samples from 4 patients that formed
neurospheres in culture. Two of these cell lines (SK72 and
SK262) also formed adherent cultures. We found that
both the neurospheres and adherent cultures expressed
equal and high levels of the neural stem cell marker
Nestin. Figure 2A shows photomicrographs representative
of Nestin staining performed on SK72 neurospheres and
SK72 adherent culture. All 8 FDA approved drugs with
activity against U87 cells also had IC50 values lower than
two currently used anti-GBM agents, vincrinstine and
irinotecan in GBM stem-like cells (neurospheres and
adherent cultures). D-actinomycin and epirubicin exhibitedFigure 2 Drug potency against stem cell-like GBM neurosphere deriv
cells growing as adherent culture and neurospheres and expressing the ne
best activity in established cell line screens tested in duplicate with adhere
exhibited the lowest IC50.the greatest potency (Figure 2B), and the liposomal form
of Doxorubicin (Doxil) was less potent than epirubicin
even though their IC50 values with U87 cells were virtually
the same (data not shown).
The topoisomerase 1B (Topo 1) inhibitor topotecan
exhibited potency that significantly surpassed the struc-
turally related Topo 1 inhibitor irinotecan. Similarly,
two statins exhibited good activity, which is promising
as these drugs have low toxicity and owing to their tar-
get pathways may enhance the activity of currently used
oncologic agents via synergism. The IC50 for pitavastatin
was less than 10 μM in most of our cells tested (a range of
1.260 to 55.63 μM). Similarly, the IC50 of sertraline was in
the range of 3.1 to 6.6 μM.ed from patient surgical isolates. (A) Photomicrographs of primary
ural stem cell marker Nestin. (B) Eight FDA approved drugs showing
nt cultures and with neurospheres. In each case D-actinomycin
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of pitavastatin
The ability of pitavastatin to cross the BBB is predicted
to be limited as the –log BB was calculated as -0.6499.
However, the drug circulates freely in plasma and may
enter the enhancing component of tumors via perme-
ation through typically leaky tumor microvessels [25,32].Effect of pitavastatin on GBM cells
Considering the effectiveness of statins in our study, spe-
cifically pitavastatin in inducing cell death and owing to
relatively fewer adverse effects, we decided to explore
pitavastatin in detail.Pitavastatin induces autophagy in GBM cells
Pitavastatin induced cell morphologic changes, as early
as 24 hours, with adherent cells assuming a rounded
configuration and detaching from the substrate (Figure 3A).
Death of tumor neurospheres was also triggered and these
cells arrested in the G0/G1 phase after treatment (Figure 3B).
G0/G1 phase cells were dominant and the proportion of
cells in S phase dramatically decreased.
We found that pitavastatin-treated GBM cells exhibited
characteristics consistent with autophagy rather than
apoptosis [20,21]. After pitavastatin treatment, GBM
cells showed extensive vacuolization, a key feature of
cellular macroautophagy [33,34]. Further, pitavastatin-
treated cells stably expressing the GFP-LC3 fusion protein
developed a punctate cytoplasmic pattern, suggesting that
GFP-LC3 covalently linked to phosphatidylethanolamine
(PE) and was inserted into double membrane autophago-
somes (Figure 3C).
Morphological observations were confirmed by Western-
blot analysis of LC3, which revealed a LC3-I to LC3-II
transition, a hallmark of autophagy (Figure 3D) [34,35].
The adherent versus sphere culture conditions did not
influence the LC3 transition, which was observed in
both U87, U251 adherent stable lines and in the stem
cell-like SK72 cell spheres upon pitavastatin treatment.
Furthermore, increasing concentrations of pitavastatin
enhanced LC3-I to II transition (Figure 3D, right panel).
In addition, Annexin staining failed to detect apoptosis
after pitavastatin (data not shown) treatment. Caspase-3/7
activity was not detectable via fluorescence or by Western-
blot analysis (Figure 3E). We could not entirely exclude
the possibility that pitavastatin induced cell apoptosis
by caspase independent pathways; however the cell
cycle analysis shown in Figure 3B argued against this
hypothesis, as it did not reveal a sub-G1 population,
characteristic of apoptotic cells. The mechanism(s) of cell
death induced by pitavastatin still needs more detailed
investigation. Further, whether other statins can also
trigger autophagy in human GBM cells remains to bedetermined, and this may depend, in part, on whether
adherent cells or neurosphere cultures are assayed.
To elucidate the possible mechanisms by which pita-
vastatin decreases cell survival, we also used a virtual
tumor cell technology. This is an in silico analysis using
a comprehensive and dynamic representation of signaling
and metabolic pathways underlying tumor physiology (based
on CellWorks Inc. technology, Additional file 2). Using
this platform, we tested the effect of pitavastatin on two
GBM cell lines (A172 and U251) using genomic profiles.
In silico modeling data predicted a significantly increase
in autophagy makers in both GBM cells following pita-
vastatin treatment (Additional file 3).
Drug combinations
We then tested 12 drugs along with pitavastatin to in-
vestigate possible additive or synergistic effects. In these
combinations tested using U87 cells, only irinotecan and
pitavastatin displayed a synergistic effect, with effective
lowering of IC50 for both compounds (Figure 4A). This
synergistic effect was further confirmed in U118 and SK72
cells, using a concentration range of pitavastatin, which
showed a dramatic 40-70 fold lowering of the IC50 com-
pared to irinotecan alone (Figure 4B). Drug combination
index (CI), calculated at ED50, ED75 and ED90, ranged
from 0.28 -0.76 for U118 cells 0.55-0.87 for U87 cells and
0.41-1.29 for SK72 cells demonstrating a moderate-to-
strong synergism between irinotecan and pitavastatin at
various drug concentrations in all three GBM cell lines.
Importantly, the addition of pitavastatin reversed the
resistance of the primary SK72 neurosphere cells to irinote-
can, causing a decrease in its IC50 from 30 μM to 1.5 μM.
Enhancement of irinotecan via suppression of MDR-1
by pitavastatin
Irinotecan induces apoptosis, which is primarily respon-
sible for its anti-tumor activity [36]. Although pitavastatin
as a single agent did not induce apoptosis, in combination
with irinotecan, it enhanced U87 caspase-3 activity as
compared to irinotecan alone, both at 12 and 24 hours
(Figure 4C). The major mechanism of drug resistance in
GBM is the over-expression of the multi-drug resistance
protein (MDR-1; p-glycoprotein 1 or ABCB1), seen in the
BBB and neuroepithelial tumors such as GBM [37]. Mul-
tiple studies have established that MDR-1 is responsible
for decreased drug accumulation in multidrug-resistant
GBM cells [38,39]. Interestingly, pitavastatin is a substrate
of MDR-1 [40]. We observed that MDR-1 gene transcrip-
tion levels correlated directly with irinotecan concentra-
tion (Figure 4D). However, after combined pitavastatin
and irinotecan treatment, the 140 KD MDR-1 band in-
creased in intensity, suggesting MDR- glycosylation is
suppressed, which attenuates the production of functional
MDR-1 (Figure 4E) [41].
Figure 3 Pitavastatin induces autophagy associated cell death for GBM. (A) Pitavastatin induced SK72 glioma primary cell death in adherent
and neurosphere cultures. Note rounding of cells at 24 h. (B) FACS analysis showing that pitavastatin treated U87 cells were arrested in G0/G1
phase with a much lower percentage of the total population in S phase. (C) In GFP-LC3 transduced-U87 GBM cells, pitavastatin induced a
punctuate GFP-LC3 distribution, which is a characteristic of autophagy. (D) Western blot showing that pitavastatin induced the transformation
of LC3 protein from isoform I to II in U87, U251 and SK72 cells. (Pitavastatin concentrations in μM). LC3I/II was calculated with NIH ImageJ
software (E) Caspase-3/7 activity in U87 cells induced by staurosporine for 8 hours detected by the Apo-One fluorescence kit. In contrast, no
caspase 3/7 activity was seen with pitavastatin treatment during 2 days. Inset: Western blot illustrating that there was no detectable cleavage
(CL) of caspase-3 after pitavastatin treatment (P, 10 μM); Staurosporine treatment (S, 0.5 μM) was used as a positive control and was associated
with caspase-3 cleavage (CL).
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As shown in Figure 4D and E, pitavastatin induced MDR-
1 mRNA and decreased glycosylation of MDR-1 protein.
To elucidate the effect of pitavastatin on MDR-1 function,
we evaluated the drug exclusion capability directly, using
the Calcein-AM assay. As showed in Figure 4F, after statin
treatment, both U87 and SK72 GBM cells showed
increased intracellular amounts of the MDR-1 substrate
(Calcein AM), indicating that pitavastatin may inhibit
drug-exclusion mediated by MDR-1. The MDR-1 inhibition
was directly proportional to pitavastatin concentration. This
result suggests that the increased caspase activity, observed
in cells treated with irinotecan in combination with pitavas-
tatin, may be due to its MDR-1 inhibitory effects, which in
turn caused accumulation of irinotecan (Figure 4C).Down-regulation of MDR-1 (ABCB1 gene) expression
correlates with overall survival and longer
disease-free status
In TCGA dataset, of the 243 GBM samples profiled, 43
showed down-regulation of MDR-1/ABCB1 (Figure 5A),
15 were amplified for MDR-1/ABCB1 and 34 had MDR-
1/ABCB1 up-regulation. This result suggested that the
MDR-1 transcription levels are variable and may be
regulated by the tumor microenvironment. In all 173
cases with normal MDR-1 expression level (blue-line),
the median survival was 14.1 months (n = 149) whereas in
patients with MDR-1 down-regulation (red-line), it was
increased to 23.2 months (P = 0.027; Figure 5B). Further,
progression-free survival increased from 6.67 months in
patients with normal MDR-1 to 11.54 months in case of
Figure 4 Pitavastatin and irinotecan exhibit synergism in terms of inducing GBM cell death in vitro. (A) U87 IC50 values for various
compounds with and without pitavastatin (2 μM), note that irinotecan IC50 was reduced by 50%. (B) Pitavastatin, sharply lowered the IC50 of
irinotecan in U118, U87 cells and SK72. The combination index calculated at ED50, ED75 and ED90. Data were calculated at two pitavastatin
concentrations. (C) Escalation of apoptosis by addition of pitavastatin to irinotecan, particularly after 12 hours of incubation. (D) Pitavastatin and
irinotecan applied singly induce MDR-1 mRNA transcription as shown by qRT-PCR, and when applied together the level of transcription is only
slightly greater than with irinotecan alone. (E) Western blot analysis indicating that after irinotecan treatment, U87 expressed full length MDR-1
(170 KD), but in combination with pitavastatin, the band density of unglycosylated MDR-1 (140 KD) increased dramatically. Unglycosylated MDR-1
cannot be transported inside the cell and is essentially non-functional. (F) After pitavastatin treatment, U87 cell and SK72 cells were accumulated
more Calcein AM and showed higher fluorescent signal than control by inhibited the MDR-1 function.
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Figure 5 Down-regulation of MDR-1 (gene ABCB1) predicted better survive for GBM patients. A) Oncoprint mRNA expression map
generated using cBio Cancer Genomics. 22% of a total of 243 GBM patients showed down-regulated MDR-1 (ABCB1) expression B) Down-regulation of
MDR-1 (red-line) increases overall patient survival as the median survival (blue-line) increased from 14.1 months to 23.2 months in Kaplan-Meier curves
(P < 0.05) and patients’ median progression-free survival increased from 6.67 to 11.54 months (P = 0.13).
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regulation or gene amplification, there was no difference
in overall or progression-free survival when compared to
controls (data not shown). These data strongly suggest
that MDR-1 inhibition following treatment with statins
may have a beneficial effect in GBM patients.Combination of Pitavastatin and Irinotecan enhances
anti-tumor efficacy in vivo
To evaluate the in vivo anti-cancer effect of pitavastatin and
irinotecan, we treated xenograft mouse models implanted
with U87 cells with either single agent or combination. As
shown in Figure 6A, low dose pitavastatin or irinotecan did
not affect tumor growth. In contrast, 0.5 mg/kg pitavastatin
in combination with 0.5 mg/kg irinotecan significantly
attenuated tumor growth (P < 0.01) compared to both the
control group and the low-dose single drug treatment
groups (one week /5 drug treatment). Tumor measure-
ments after sacrificing the mice at day 32 confirmed that
combination treatment significantly reduced tumor size
and weight (P < 0.001; Figure 6A, right panel). Interest-
ingly, irinotecan administered as a single agent but at a
dose 10-times higher than that used in the combination
treatment group was also very potent in inhibiting in vivo
U87 tumor growth. However, such high doses were associ-
ated with significant drug toxicity, as indicated by severe
weight loss in drug-treated mice (Figure 6B). In contrast,
the body weights of mice receiving a combination of pita-
vastatin and low-dose irinotecan increased 3-4 gram
steadily similar to that seen in control and the low dose
drug treatment groups during the whole study duration.
Moreover, tumor cell proliferation decreased dramatically
as showed by the Ki67 staining in Figure 6C.Discussion
In the present study, we sought to screen a library of
FDA-approved compounds to rapidly identify new, non-
GBM drugs that could be readily introduced into GBM
clinical trials. Using a platform that employed a wide range
of human GBM lines, including clinically relevant patient-
derived primary GBM lines, our screening uncovered
22 compounds from different classes with anti-neoplastic
activity in GBM. Among others, the cardiovascular drugs
statins showed high efficacy in reducing tumor growth
both in vitro and in vivo, drawing our attention to these
relatively non-toxic cholesterol lowering drugs. The
present study demonstrates the potency of pitavastatin
relative to other statins. Importantly, our results demon-
strated that co-administration of pitavastatin with low-dose
chemotherapy, greatly increased the potency of the latter,
lowering the IC50 values for irinotecan by 40- to 70-fold,
with few adverse effects. Experimentally, we found that
statins independently induced autophagy in GBM and
that statins may potentiate chemotherapeutic agents by
inhibiting MDR-1 function. This was consistent with
in silico screening results using our virtual tumor cell
technology, which suggested that pitavastatin affects
cell viability by inducing autophagy.
Cholesterol has a key role in cell membranes, cell me-
tabolism, cell signaling and has been implicated in tumor
development and progression. Therefore, as cholesterol-
lowering agents, questions about the anti-tumor effects
of statins have been already posed [42,43]. Statins decrease
cholesterol levels by inhibiting the enzyme HMG-CoA
reductase in the liver. In addition, mevalonate, and isopren-
oid intermediates such as geranylgeranylpyrophosphate
(GGPP) and farnesylpyrophosphate (FPP) in the cholesterol






Figure 6 Co-administration of low dose of pitavastatin and irinotecan inhibited tumor growth in vivo. A) U87 tumor growth
was inhibited by combination treatment but not by low dose of single drug; tumor volume and weight dramatically decreased following
combination treatment when compared to control and single drug-treated groups. B) A combination of low dose pitavastatin and irinotecan
showed no toxicity whereas high dose irinotecan induced mice body weight loss. C) H&E and Ki-67 staining of control and combination treatment
of in vivo U87 tumor model, showed a much lower proliferation in the tumor cells after combination treatment.
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for protein N-glycosylation, is also blocked by statins
[45,46]. Considering that GBMs are highly proliferative
taking up large quantities of cholesterol, potentially they
may be vulnerable to statin treatment [47,48]. However,
the mechanism of sensitivity of GBM to statins has not
been elucidated. Recent studies have shown that statins
may have an anti-GBM effect in xenograft mouse models,
by targeting the low-density lipoprotein receptor (LDLR),
inducing apoptosis via ERK/AKT pathway [20,47]. Other
data hypothesize that statins may inhibit tumor growth by
inducing autophagy via the NF-κB pathway in human
colon cancer cell line [49]. Our data obtained in both
stable cell lines and primary patient samples clearly
demonstrated that pitavastatin induced macro-autophagy
in GBM cells [20,21]. Further experiments are now
ongoing to investigate the signaling pathway(s) involved in
this effect.
Importantly, we have shown that pitavastatin potentiated
the anti-tumor effects of low-dose irinotecan, a topoisom-
erase inhibitor. Pitavastatin is know to be a substrate of
the multi-drug resistance protein, MDR-1, which is over-
expressed in GBM upon drug treatment and is partly
responsible for the resistance of GBM to chemotherapy.
Our data indicate that, in combination with irinotecan,
pitavastatin suppressed glycosylation of MDR-1, thereby
inhibiting its function and allowing irinotecan to accumu-late intracellularly [37,39,40]. Accumulation of irinotecan
is likely responsible for the increased apoptosis in the
presence of pitavastatin. The MDR-1 expression in cancer
cells can be a significant obstacle to the success of chemo-
therapy. Many MDR-1 inhibitors have been extensively
tested in clinical trials but the results have been inconclu-
sive. According to TCGA data, down-regulated ABCB1
(MDR-1) predicted better survival of GBM patients. Com-
bining a statin with a chemotherapeutic agent represents
a powerful, potential strategy for circumventing resist-
ance and significantly enhancing efficacy. Here we have
confirmed that pitavastatin may improve the therapeutic
response to TOPO-1 inhibitors, by inhibiting MDR-1
function, and may be beneficial for GBM patients. It
remains to be determined whether other statins exert a
similar or a different anti-neoplastic mechanism as com-
pared to pitavastatin, and whether different subtypes of
GBM have different sensitivity to pitavastatin or display
other mechanisms for statin actions. GBM is a complex
and heterogeneous disease that likely accounts for the
different results obtained across various studies.
Irinotecan is broadly used in solid cancer therapy,
especially in combination with other drugs [50,51]. In
clinical use, the toxicity of irinotecan is generally manage-
able and reversible [52,53]. However, in some patients it
may lead to severe side effects, such as diarrhea and neu-
tropenia that can be life threatening. In our animal model,
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dosage of irinotecan and avoided drug toxicity at higher
dosage. These data indicate a new strategy to develop
better irinotecan-based drug combination.
Based on the promising results of our present study,
we are now undertaking additional preclinical studies of
GBM to optimize dosing and characterize efficacy, thus
providing a solid basis for a clinical trial with pitavastatin
and irinotecan for the treatment of glioblastoma patients.
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